yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
Today's Top SOA Links

Eventide Gilead Fund Announces 2012 Results

BOSTON, MA -- (Marketwire) -- 01/22/13 -- The Eventide Gilead Fund (NASDAQ: ETGLX), a mutual fund practicing biblically responsible investing, achieved a one-year total return of 18.15%, compared with the Russell Mid-Cap Growth Index return of 15.81% and S&P 500 Index return of 16.00%, outperforming each by 2.34% and 2.15% (respectively). The Fund finished the year ranking in the top 8% of its peer group (Mid-Cap Growth) for total performance according to Morningstar, out of 400 funds.

The following table shows the Gilead Fund's performance since inception:

                                                             Since inception
                                       1 year      3 year      (7/08/2008)
 As of 12/31/2012        YTD return    return    annualized    annualized
                                                   return        return
Eventide Gilead Fund*      18.15%      18.15%      11.95%        11.08%
S&P 500 Total Return
Index                      16.00%      16.00%      10.87%         4.88%
Russell Mid-Cap Growth
Total Return Index         15.81%      15.81%      12.91%         6.00%

The Eventide Gilead Fund maintains its distinctive investment strategy of finding and investing in companies that "serve -- or 'create value,'" said Eventide lead portfolio manager Finny Kuruvilla, MD PhD. "Value creation is the business application of 'the golden rule,' the hallmark of the Christian ethic, but also, we believe, the key indicator of business vitality and the most reliable leading indicator of financial performance."

"Businesses that prosper best over the long-term are those that serve important needs especially well; those that lose sight of this purpose invariably shift focus inwardly to shareholders, where brand posturing and 'next quarter'-thinking cost meaningful innovation -- and eventually profits," continued Kuruvilla. "Our commitment to looking for companies that serve, however, we believe has been precisely the reason Gilead Fund investors have benefited over the past four and half years, including in 2012."

The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, a Boston-based investment advisor.

Expenses ratios: Gross Expenses 2.05%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses at 1.64% until at least October 31, 2013. Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the fund's prospectus for more information regarding the fund's fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

Morningstar ratings and classifications do not constitute and are not intended to constitute investment advice. As a result, you should not make an investment decision on the basis of this information. Rather, you should use Morningstar ratings and classifications for informational purposes only.

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.

Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.

An investor should consider the Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund's prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836). You can also obtain a prospectus at The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide Asset Management, LLC.

Add to Digg Bookmark with Add to Newsvine

Fund Contact:
Robin John
877-771-EVEN (3836), x55

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Intuit uses deep-data analytics to gain a 360-degree view of its TurboTax application's users’ behavior and preferences for rapid applications improvements. The next BriefingsDirect big-data innovation case study highlights how Intuit uses deep-data analytics to gain a 360-degree view...
Certain CIOs for incomprehensible reasons keep off their cloud transformation projects several key IT disciplines including Enterprise Architecture (EA), IT Service Management (ITSM) and most importantly Project Management. Do they consider them obsolete? useless? irrelevant? ITaaS St...
This is how a typical software product lifecycle works : You gather requirements, build a prototype, detail out the architecture and design, develop the product, test it, deploy the product, handle migration and maintenance and ensure product support. This is a closed loop where the Pr...
In today’s pharmaceutical supply chain, counterfeit activity is thriving. As pharma companies have expanded target markets and outsourced production over the last decade, the supply chain has become increasingly global, virtual, and vulnerable. Illicit activity has thrived, and patient...
Here’s the thing: as sure as we’ll have another record-setting year for NFL streaming, you can also be sure that apps will fail and streaming services will go down. Whether you are dabbling in streaming or diving in whole-hog, you need to know what to do to give your users the most rel...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers